January 11, 2021
 

Late in 2020, DeCell Technologies released a "flourish of announcements – including a unique patent approval – that position the Halifax-area life sciences company for growth in 2021. The company, which makes a natural regenerative scaffolding for wounds, said in November that it had obtained patents for its “prECM decellularization technology” in the U.S., Canada, and five European countries – the U.K., France, Spain, Germany and Italy. What’s interesting about the approval is that the patent covers not just a product or piece of technology but the process used in producing DeCell’s "flagship product DermGEN.

Two months earlier, the company unveiled a regional distribution agreement with Impactful Health Solutions of New Jersey and Pharmed Healthcare of Cairo. Under this deal, DermGEN can be sold into eight countries in the Middle East and Northern Africa. These are the latest chapters in an eight-year journey in which Chief Science Officer Paul Gratzer and COO Sean Margueratt have worked to improve the treatment of chronic foot ulcers, which are a common and dangerous ailment suffered by diabetics. Working with partners from around the world, they are trying to give healthcare workers not only better tools for treating this affliction but also enhanced knowledge and best practice.